Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study
Mark A. Socinski, MD, reviews data from the PAPILLON study presented at ESMO 2023 on amivantamab plus chemotherapy vs chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.
Novel HER2-Targeted Therapies for NSCLC
Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.
Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Unmet Needs in NSCLC Therapy
Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Major Adverse Events of Anti-HER2 Therapies
Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
HER2-Targeted Therapies in NSCLC
Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Current Treatment Options in NSCLC
Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.
Testing Patients with NSCLC for HER2 Mutations
Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
The Role of HER2 Alterations in NSCLC
Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.
HER2 Alterations in NSCLC: Clinical Scenario
Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.
Liquid vs Solid Tumor Biopsies in NSCLC
Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.
Approaches to Biomarker Testing in NSCLC
Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.
Biomarker Testing in NSCLC: Clinical Scenario
A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.
Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer
Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.
Clinical Management of NTRK+ Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.
Clinical Management of RET+ Advanced NSCLC
Mark Socinski and Stephen Liu describe the current treatment options for patients with RET+ NSCLC. They also summarize recent clinical data for agents that target RET.
RET Alterations in Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a RET alteration in NSCLC and its value as a targetable biomarker.
Clinical Management of ROS1+ Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ROS1+ NSCLC. They also summarize recent clinical data for agents that target ROS1.
ROS1 Alterations in Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu explain the role of a ROS1 alteration in NSCLC and its value as a targetable biomarker.
Clinical Management of ALK+ Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with ALK+ NSCLC. They also summarize recent clinical data for ALK inhibitors.
ALK Alterations in Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu explain the role of an ALK alteration in NSCLC and its value as a targetable biomarker.
Testing for Gene Alterations and Protein Expression in Advanced NSCLC
Ben Levy, Mark Socinski, and Stephen Liu explain the various types of genetic alterations and protein expressions that are targetable in NSCLC and the crucial role of comprehensive genetic testing at the time of diagnosis and at the time of disease progression.
Overview of Targeted Therapies, Improved Outcomes, and Unmet Needs in Advanced NSCLC
An increased understanding of driver gene alterations in advanced non–small cell lung cancer (NSCLC) has led to the development of targeted therapies that offer improved patient outcomes. Ben Levy, MD; Mark A. Socinski, MD; and Stephen Liu, MD, share their thoughts on the emerging treatment landscape and remaining unmet needs.
Final Thoughts on Effective Therapy and Financial Toxicity
Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.
Innovation of Therapies vs Disruptive Pricing
A panel of experts debate the cost of innovation vs disruptive pricing of therapy.
Mitigating Strategies Appropriate for EGFR Therapy and Financial Toxicity
Jack West, MD, and Gilberto Lopes, MD, share their thoughts on mitigating strategies of therapy associated with financial toxicity.
Review of GEMSTONE-301 and -302 Data
Mark Socinski, MD, and Jack West, MD, review the GEMSTONE-301 and GEMSTONE-302 trials.
Significance of PD-L1/PD-1 Testing in NSCLC
A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.
Pharmacoeconomic Considerations for Immunotherapy
Gilberto Lopes, MD, Jack West, MD, and Mark Socinski, MD, provide their insight on the pharmacoeconomic considerations for immunotherapy.
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
2 Clarke Drive Cranbury, NJ 08512